# MSC

## Overview
The MSC gene encodes musculin, a basic helix-loop-helix (bHLH) transcription factor that plays a pivotal role in muscle development and immune regulation. Musculin is involved in the formation of homodimers and heterodimers, which are essential for its function as a transcriptional repressor. It binds to specific DNA motifs, such as the E-box, to regulate gene expression during cellular differentiation processes, including the development of induced regulatory T cells (iTregs) and the repression of T helper 2 (TH2) transcriptional programs. The MSC gene is also implicated in certain pathological conditions, such as anaplastic large cell lymphoma (ALCL), where mutations can disrupt its normal function, leading to aberrant cell proliferation. Understanding the structure and function of musculin provides insights into its regulatory roles in both normal physiological and disease contexts (Zhao2006Musculin; Wu2017The; Luchtel2019Recurrent).

## Structure
Musculin (MSC) is a basic helix-loop-helix (bHLH) transcription factor involved in muscle development and regulation. The primary structure of MSC includes two isoforms: Musculin 1a, consisting of 201 amino acids, and Musculin 1b, a shorter variant with 180 amino acids. The Musculin 1b isoform arises from alternative splicing, resulting in a transcript with three exons and a different reading frame at the 3' end, leading to a distinct C-terminal region (Zhao2006Musculin).

The secondary structure of MSC is characterized by the presence of a basic domain for DNA binding and a helix-loop-helix domain for dimerization, which are typical features of bHLH proteins (Zhao2006Musculin). These structural elements facilitate the formation of homodimers or heterodimers, allowing MSC to bind to specific DNA motifs such as the E-box (Yan2021The).

In terms of quaternary structure, MSC can form homodimers or heterodimers with E-proteins, influencing its role as a transcriptional repressor (Torres-Machorro2021Homodimeric). The repressor domain of MSC is located between amino acids 158 and 173, which is crucial for its function in antagonizing MyoD activation (Zhao2006Musculin).

## Function
Musculin (MSC) is a basic helix-loop-helix (bHLH) transcription factor that plays a significant role in regulating gene expression during cellular differentiation. In healthy human cells, MSC is involved in the development of induced regulatory T cells (iTregs) by repressing the T helper 2 (TH2) transcriptional program. This repression is crucial for maintaining immune homeostasis and tolerance, particularly at mucosal sites. MSC enforces the expression of Foxp3, a key regulator of Treg function, while restraining the development of TH2 gene programs (Wu2017The).

MSC functions as a transcriptional repressor by interacting with E2A proteins and forming inactive heterodimers. It also forms a complex with GATA3, a key TH2 transcription factor, to inhibit TH2 gene expression during iTreg differentiation. This suggests that MSC is a negative regulator of the chromatin architecture required for TH2 locus activation (Wu2017The). In MSC-deficient iTregs, there is impaired expression of Foxp3, leading to a reduced ability to inhibit the proliferation of naive CD4+ T cells and a failure to suppress TH2 responses (Wu2017The). These functions highlight MSC's critical role in immune regulation and its potential implications for inflammatory conditions.

## Clinical Significance
Mutations in the MSC gene, specifically the MSC E116K mutation, have been implicated in the pathogenesis of anaplastic large cell lymphoma (ALCL), particularly in ALK-negative subtypes. This mutation disrupts the normal function of musculin by sequestering basic helix-loop-helix (bHLH) proteins, preventing DNA binding, and inhibiting E2F2-mediated repression of CD30. This leads to increased expression of the CD30-IRF4-MYC axis, promoting tumor cell proliferation and growth (Luchtel2019Recurrent). The MSC E116K mutation is associated with DUSP22 rearrangements in ALCLs and is linked to a higher proliferative rate in these lymphomas (Luchtel2019Recurrent).

The mutation's role in ALCL suggests potential therapeutic targets, as cells with the MSC E116K mutation show increased sensitivity to BET inhibitors like JQ1, which could be explored for treatment (Luchtel2019Recurrent). The mutation's impact on the CD30-IRF4-MYC axis and its association with DUSP22 rearrangements highlight its significance in the clinical progression and potential treatment strategies for ALCL (Luchtel2019Recurrent).

## Interactions
Musculin (MSC) is a basic helix-loop-helix (bHLH) transcription factor that interacts with various proteins and nucleic acids, influencing gene expression and cellular processes. MSC forms heterodimers with E-proteins, such as E12, to bind to E-boxes, which are specific DNA motifs recognized by bHLH proteins (MacQuarrie2013Genomewide). This interaction allows MSC to compete with MyoD for binding sites, thereby modulating MyoD's activity and influencing myogenic differentiation (MacQuarrie2013Genomewide).

MSC has a more relaxed sequence preference compared to MyoD, allowing it to bind to a broader range of DNA sequences. This characteristic enables MSC to buffer MyoD's binding activity by occupying potential MyoD binding sites and sequestering E-proteins (MacQuarrie2013Genomewide). MSC's binding is enriched at DNase hypersensitive sites and regions with higher levels of histone acetylation, indicating its association with open chromatin regions (MacQuarrie2013Genomewide).

In addition to heterodimerization, MSC can form homodimers, which are transcriptionally inactive or act as repressors. These homodimers can bind DNA but remain inactive, potentially sequestering components necessary for active dimer formation (Torres-Machorro2021Homodimeric). These interactions highlight MSC's role as a regulatory factor in muscle development and regeneration.


## References


[1. (Wu2017The) Chuan Wu, Zuojia Chen, Valerie Dardalhon, Sheng Xiao, Theresa Thalhamer, Mengyang Liao, Asaf Madi, Rafael F Franca, Timothy Han, Mohammed Oukka, and Vijay Kuchroo. The transcription factor musculin promotes the unidirectional development of peripheral treg cells by suppressing the th2 transcriptional program. Nature Immunology, 18(3):344–353, January 2017. URL: http://dx.doi.org/10.1038/ni.3667, doi:10.1038/ni.3667. This article has 50 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ni.3667)

[2. (Torres-Machorro2021Homodimeric) Ana Lilia Torres-Machorro. Homodimeric and heterodimeric interactions among vertebrate basic helix–loop–helix transcription factors. International Journal of Molecular Sciences, 22(23):12855, November 2021. URL: http://dx.doi.org/10.3390/ijms222312855, doi:10.3390/ijms222312855. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms222312855)

[3. (Zhao2006Musculin) Po Zhao and Eric P. Hoffman. Musculin isoforms and repression of myod in muscle regeneration. Biochemical and Biophysical Research Communications, 342(3):835–842, April 2006. URL: http://dx.doi.org/10.1016/j.bbrc.2006.01.188, doi:10.1016/j.bbrc.2006.01.188. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2006.01.188)

[4. (Yan2021The) Jun Yan, Jing Yu, Ke Liu, Yijia Liu, Changchuin Mao, and Wenda Gao. The pathogenic roles of il-22 in colitis: its transcription regulation by musculin in t helper subsets and innate lymphoid cells. Frontiers in Immunology, December 2021. URL: http://dx.doi.org/10.3389/fimmu.2021.758730, doi:10.3389/fimmu.2021.758730. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2021.758730)

[5. (MacQuarrie2013Genomewide) Kyle L MacQuarrie, Zizhen Yao, Abraham P Fong, and Stephen J Tapscott. Genome-wide binding of the basic helix-loop-helix myogenic inhibitor musculin has substantial overlap with myod: implications for buffering activity. Skeletal Muscle, November 2013. URL: http://dx.doi.org/10.1186/2044-5040-3-26, doi:10.1186/2044-5040-3-26. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/2044-5040-3-26)

[6. (Luchtel2019Recurrent) Rebecca A. Luchtel, Michael T. Zimmermann, Guangzhen Hu, Surendra Dasari, Manli Jiang, Naoki Oishi, Hailey K. Jacobs, Yu Zeng, Tanya Hundal, Karen L. Rech, Rhett P. Ketterling, Jeong-Heon Lee, Bruce W. Eckloff, Huihuang Yan, Krutika S. Gaonkar, Shulan Tian, Zhenqing Ye, Marshall E. Kadin, Jagmohan Sidhu, Liuyan Jiang, Jesse Voss, Brian K. Link, Sergei I. Syrbu, Fabio Facchetti, N. Nora Bennani, Susan L. Slager, Tamas Ordog, Jean-Pierre Kocher, James R. Cerhan, Stephen M. Ansell, and Andrew L. Feldman. Recurrent msce116k mutations in alk-negative anaplastic large cell lymphoma. Blood, 133(26):2776–2789, June 2019. URL: http://dx.doi.org/10.1182/blood.2019000626, doi:10.1182/blood.2019000626. This article has 54 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood.2019000626)